Logo Image
|Videos|September 9, 2022

The future of ibrexafungerp for prevention of recurrent yeast infections

Author(s)Morgan Ebert

Nkechi Azie, MD, MBA, FIDSA, vice president of clinical development and medical affairs at SCYNEXIS, discusses the potential FDA approval of ibrexafungerp (Brexafemme; SCYNEXIS) for the prevention of recurrent vulvovaginal candidiasis.

Note: BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp. Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting.

Related Content

Latest CME

Join Us at The Pathology Meeting in Las Vegas
In-Person + Virtual Event

Join Us at The Pathology Meeting in Las Vegas

October 5, 2026

View more
Join Us at The Pathology Meeting in Las Vegas
In-Person + Virtual Event

Join Us at The Pathology Meeting in Las Vegas

October 4-5, 2026

View more
SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer
Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

View more